Acquired resistance to crizotinib from a mutation in CD74-ROS1

New England Journal of Medicine

Volumn 369, Issue 12, 2013, Pages 1172-1173

  Gerlinger, Marco ^a   Norton, Larry ^b   Swanton, Charles ^a  

^a London Research Institute   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; CRIZOTINIB; PROTEIN; PROTEIN ROS1; UNCLASSIFIED DRUG;

CANCER LOCALIZATION; CD74 GENE; GENE; GENE FREQUENCY; GENE MUTATION; HUMAN; HYPOTHESIS; LETTER; LUNG CANCER; METASTASIS; MOLECULAR CLONING; PHYLOGENY; PRIORITY JOURNAL; ROS1 GENE;

EID: 84884181581     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1309091     Document Type: Letter

References (4)

1. Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74 -ROS1. N Engl J Med 2013;368:2395-401.
2. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139:1315-26.
3. Newton PK, Mason J, Bethel K, et al. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res 2013;73:2760-9.
4. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92. [Erratum, N Engl J Med 2012;367:976.]